Cerebral Embolic Protection Devices: Are There Any Indications in Transcatheter Aortic Valve Replacement?

被引：0

作者：

Sayah, Neila ^{[1
]}

Skalidis, Ioannis ^{[2
]}

Mesnier, Jules ^{[3
]}

Neylon, Antoinette ^{[1
]}

Akodad, Mariama ^{[1
]}

Asgar, Anita ^{[4
]}

机构：

[1] Hop Jacques Cartier, Inst Cardiovasc Paris Sud, Ramsay St, F-91300 Massy, France

[2] Lausanne Univ Hosp CHUV, Dept Cardiol, CH-1011 Lausanne, Switzerland

[3] Hop Bichat Claude Bernard, Assistance Publ Hop Paris, Dept Cardiol, F-75018 Paris, France

[4] Montreal Heart Inst, Dept Cardiol, Montreal, PQ H1T 1C8, Canada

来源：

JOURNAL OF CLINICAL MEDICINE | 2024年 / 13卷 / 18期

关键词：

aortic stenosis; cerebral embolic protection devices; stroke; transcatheter aortic valve replacement; RANDOMIZED EVALUATION; DEFLECTION DEVICE; IMPLANTATION; PERFORMANCE; STENOSIS; LESIONS; SAFETY; STROKE; SYSTEM; IMPACT;

D O I：

10.3390/jcm13185471

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Stroke following transcatheter aortic valve replacement (TAVR) is a significant and life-threatening adverse event. The vast majority of these incidents occur during the TAVR procedure or within the first 24 h following TAVR, with a notable prevalence of cerebral embolic events. In response to this concern, cerebral embolic protection devices (CEPDs) have been designed to mitigate the risk of peri-procedural ischemic stroke during TAVR. The primary objective of CEPDs is to diminish the intraprocedural burden associated with new silent ischemic brain injuries. Despite the development of several CEPDs, their clinical efficacy remains uncertain. In this review, we delve into a comprehensive analysis of the utilization of CEPDs in patients undergoing TAVR, exploring insights from the existing literature. Additionally, we aim to present future perspectives and discuss the clinical implications associated with the incorporation of CEPDs in TAVR procedures.

引用

页数：15

共 39 条

[1] [Anonymous], 2020, ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association
[2] Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study
Baumbach, Andreas
Mullen, Michael
Brickman, Adam M.
Aggarwal, Suneil K.
Pietras, Cody G.
Forrest, John K.
Hildick-Smith, David
Meller, Stephanie M.
Gambone, Louise
den Heijer, Peter
Margolis, Pauliina
Voros, Szilard
Lansky, Alexandra J.
[J]. EUROINTERVENTION, 2015, 11 (01) : 75 - 84
[3] Late stroke after transcatheter aortic valve replacement: a nationwide study
Bjursten, Henrik
Norrving, Bo
Ragnarsson, Sigurdur
[J]. SCIENTIFIC REPORTS, 2021, 11 (01)
[4] Transcatheter aortic valve replacement in low risk patients: a review of PARTNER 3 and Evolut low risk trials
Braghiroli, Joao
Kapoor, Kunal
Thielhelm, Torin P.
Ferreira, Tanira
Cohen, Mauricio G.
[J]. CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2020, 10 (01) : 59 - 71
[5] Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
Brouwer, Jorn
Nijenhuis, Vincent J.
Delewi, Ronak
Hermanides, Renicus S.
Holvoet, Wouter
Dubois, Christophe L. F.
Frambach, Peter
De Bruyne, Bernard
van Houwelingen, Gert K.
Van der Heyden, Jan A. S.
Tousek, Petr
van der Kley, Frank
Buysschaert, Ian
Schotborgh, Carl E.
Ferdinande, Bert
van der Harst, Pim
Roosen, John
Peper, Joyce
Thielen, Frederick W. F.
Veenstra, Leo
Yin, Dean R. P. P. Chan Pin
Swaans, Martin J.
Rensing, Benno J. W. M.
van 't Hof, Arnoud W. J.
Timmers, Leo
Kelder, Johannes C.
Stella, Pieter R.
Baan, Jan
ten Berg, Jurrien M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) : 1447 - 1457
[6] A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement
Dangas, George D.
Tijssen, Jan G. P.
Woehrle, Jochen
Sondergaard, Lars
Gilard, Martine
Moellmann, Helge
Makkar, Raj R.
Herrmann, Howard C.
Giustino, Gennaro
Baldus, Stephan
De Backer, Ole
Guimaraes, Ana H. C.
Gullestad, Lars
Kini, Annapoorna
von Lewinski, Dirk
Mack, Michael
Moreno, Raul
Schaefer, Ulrich
Seeger, Julia
Tchetche, Didier
Thomitzek, Karen
Valgimigli, Marco
Vranckx, Pascal
Welsh, Robert C.
Wildgoose, Peter
Volkl, Albert A.
Zazula, Ana
van Amsterdam, Ronald G. M.
Mehran, Roxana
Windecker, Stephan
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (02) : 120 - 129
[7] Evolution, Predictors, and Neurocognitive Effects of Silent Cerebral Embolism During Transcatheter Aortic Valve Replacement
De Carlo, Marco
Liga, Riccardo
Migaleddu, Gianmichele
Scatturin, Melania
Spaccarotella, Carmen
Fiorina, Claudia
Orlandi, Giovanni
De Caro, Francesco
Rossi, Marco L.
Chieffo, Alaide
Indolfi, Ciro
Reimers, Bernhard
Cosottini, Mirco
Petronio, A. Sonia
[J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (11) : 1291 - 1300
[8] Cerebral embolic protection during transcatheter heart interventions
Diaz, Victor Alfonso Jimenez
Kapadia, Samir R.
Linke, Axel
Mylotte, Darren
Lansky, Alexandra
Grube, Eberhard
Settergren, Magnus
Puri, Rishi
[J]. EUROINTERVENTION, 2023, 19 (07) : 549 - 570
[9] Final report of the PROTEMBO C Trial: a prospective evaluation of a novel cerebral protection device during TAVI
Fezzi, Simone
Jagielak, Dariusz
Targonski, Radoslaw
Schmidt, Tobias
Frerker, Christian
Witkowski, Adam Ryszard
Lauterbach, Michael
Leick, Juergen
Erglis, Andrejs
Narbute, Inga
Grygier, Marek
Misterski, Marcin
Frank, Derk
Abdel-Wahab, Mohamed
Wilde, Johannes
Adam, Matti
Gatto, Fernando
Zivadinov, Robert
Dwyer, Michael
Werner, Nikos
Mylotte, Darren
[J]. EUROINTERVENTION, 2024, 20 (04) : e264 - e267
[10] Predictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study
Grubman, Daniel
Ahmad, Yousif
Leipsic, Jonathon A.
Blanke, Philipp
Pasupati, Sanjeevan
Webster, Mark
Nazif, Tamin M.
Parise, Helen
Lansky, Alexandra J.
[J]. AMERICAN JOURNAL OF CARDIOLOGY, 2023, 207 : 28 - 34

← 1 2 3 4 →